Dalton Pharma Services Supports Client Milestone in Dengue Treatment Clinical Trial – Technology News – redOrbit

The Phase 1b clinical trial to evaluate Celgosivir as a treatment Against Dengue (CELADEN) has opened for enrolment at the Singapore General Hospital’s Investigational Medicine Unit. This follows the successful completion of development of the active pharmaceutical ingredient (API) and manufacturing of the final dosage form by Dalton Pharma Services and subsequent approval for the clinical trial by the Health Sciences Authority of Singapore and the hospital’s Institutional Review Board.

via Dalton Pharma Services Supports Client Milestone in Dengue Treatment Clinical Trial – Technology News – redOrbit.

Advertisements


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s